TriangleNCT00075829 · OUTCOME
Cumulative Incidence of Progression/Relapse
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of patients
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Year 3
What was measured
Patients are considered experiencing an event when they progress. Deaths without progression are considered as a competing risk. Patients initiating non-protocol anti-myeloma therapy are considered to have progressed on this protocol.
Analysis population: Patients that completed second transplant
Groups in this outcome
Auto-Auto Standard Risk
Tandem autologous transplant plus thalidomide/dexamethasone or observation for standard risk patients
Auto-Allo Standard Risk
Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients
Auto-Auto High Risk
Tandem autologous transplant plus thalidomide/dexamethasone or observation for high risk patients
Auto-Allo High Risk
Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients
| Group | Source count |
|---|---|
| Auto-Auto Standard Risk | 366 |
| Auto-Allo Standard Risk | 156 |
| Auto-Auto High Risk | 31 |
| Auto-Allo High Risk | 29 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Auto-Auto Standard Risk | 50 | Not reported | 46 | 55 | Not reported |
| Auto-Allo Standard Risk | 46 | Not reported | 39 | 54 | Not reported |
| Auto-Auto High Risk | 57 | Not reported | 42 | 71 | Not reported |
| Auto-Allo High Risk | 38 | Not reported | 22 | 54 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 46
- upper Limit
- 55
- value
- 50
- group Id
- OG001
- lower Limit
- 39
- upper Limit
- 54
- value
- 46
- group Id
- OG002
- lower Limit
- 42
- upper Limit
- 71
- value
- 57
- group Id
- OG003
- lower Limit
- 22
- upper Limit
- 54
- value
- 38
- denoms
- counts
- group Id
- OG000
- value
- 366
- group Id
- OG001
- value
- 156
- group Id
- OG002
- value
- 31
- group Id
- OG003
- value
- 29
- units
- Participants
- description
- Patients are considered experiencing an event when they progress. Deaths without progression are considered as a competing risk. Patients initiating non-protocol anti-myeloma therapy are considered to have progressed on this protocol.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Tandem autologous transplant plus thalidomide/dexamethasone or observation for standard risk patients
- id
- OG000
- title
- Auto-Auto Standard Risk
- description
- Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients
- id
- OG001
- title
- Auto-Allo Standard Risk
- description
- Tandem autologous transplant plus thalidomide/dexamethasone or observation for high risk patients
- id
- OG002
- title
- Auto-Auto High Risk
- description
- Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients
- id
- OG003
- title
- Auto-Allo High Risk
- param Type
- NUMBER
- population Description
- Patients that completed second transplant
- reporting Status
- POSTED
- time Frame
- Year 3
- title
- Cumulative Incidence of Progression/Relapse
- type
- SECONDARY
- unit Of Measure
- percentage of patients
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice